UNSPSC 51372029: Metopon hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C18H21NO3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6O34Q1K8M6. Most nations, for tariff and trade purposes, schedule metopon hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, METOPON HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Metopon hydrochloride bears US NLM identifiers UMLS ID C0956898 and NCI Concept Code C83964. SMILES: C[C@]12C(=O)CC[C@@H]3[C@]14CCN([C@@H]3CC5C4C(C(CC5)O)O2)C.CL.

UNSPSC 51372029 Metopon hydrochloride is a Commodity code that does not reflect the actual procurement activity tagged under it. The single recent state and local solicitation on record — Seminole County, Florida's IFB60459723LAS — sought naloxone and drug deactivation systems, not metopon hydrochloride, an opioid pharmaceutical distinct from naloxone. The code's nominal scope (metopon hydrochloride, a controlled substance used in pain management and opioid-use-disorder treatment) does not align with the posted opportunity, which targets naloxone (an opioid antagonist) and ancillary drug deactivation equipment for community health support.

Seminole County posted the IFB on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a competitive bid basis. Quarterly deliveries were required to the Seminole County Community Health Building in Sanford, Florida, with vendors responsible for all shipping and delivery costs. The contract included a two-year initial term with a one-year renewal option, compliance requirements including drug-free workplace certification and E-Verify verification, and potential FEMA funding with associated federal regulatory oversight. The procurement shows little relevant recent activity aligned with the code's actual pharmaceutical scope.